 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
3 News |  |
- || Eucrisa (crisaborole) / Pfizer, AN2898 / Pfizer
Retrospective data, Review, Journal: Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis. (Pubmed Central) - Feb 14, 2020
This meta-analysis suggests that topical PDE4 inhibitors are a safe and effective treatment for mild to moderate AD. Current evidence supports the use of crisaborole or AN2898 as the choice of maintenance or sequential therapy for mild to moderate AD.
- | Eucrisa (crisaborole) / Pfizer, AN2898 / Pfizer
Enrollment change: Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov) - Dec 12, 2011
P2, N=46, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Current evidence supports the use of crisaborole or AN2898 as the choice of maintenance or sequential therapy for mild to moderate AD. N=80 --> 46
- | Eucrisa (crisaborole) / Pfizer, AN2898 / Pfizer
Trial completion: Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov) - Dec 12, 2011
P2, N=46, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
N=80 --> 46 Active, not recruiting --> Completed